Nurix Therapeutics Q2 EPS $(0.45) Beats $(0.56) Estimate, Sales $30.68M Beat $26.21M Estimate
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics reported Q2 earnings per share (EPS) of $(0.45), beating the analyst consensus estimate of $(0.56) by 19.64%. This is a 55.45% increase over losses from the same period last year. The company also reported quarterly sales of $30.68 million, beating the analyst consensus estimate of $26.21 million by 17.04%. This is a 168.33% increase over sales from the same period last year.
July 13, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics reported better than expected Q2 earnings and sales, showing significant year-over-year growth.
Nurix Therapeutics reported Q2 earnings and sales that beat analyst estimates, which is typically a positive signal for the stock. The significant year-over-year growth in both earnings and sales suggests that the company's financial performance is improving, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100